NR3C1 and breast carcinoma: On the one hand, there is considerable interindividual variability in patient sensitivity to glucocorticoids, partly attributable to GR genetic polymorphisms and heterogeneity in GR expression levels and signaling pathways across different breast cancer subtypes, which may lead to inconsistent efficacy at standard doses.